# Wuhan Mairui Bio-Medical Technology (Mindray Wuhan subsidiary)
武汉迈瑞生物医疗科技有限公司 (Wuhan Mairui Bio-Medical Technology Co., Ltd.) was a wholly owned medical-device subsidiary of Mindray Medical in Wuhan's East Lake High-tech Development Zone (Optics Valley), incorporated on December 24, 2019 and deregistered in December 2025 after being absorbed by merger into Wuhan Mindray Scientific Co., Ltd.[1](https://www.tianyancha.com/company/3400983339) • [2](https://www.vcbeathealth.com/article/5290) It was not an independent startup but the registry vehicle for Mindray's Global Second Headquarters and Wuhan Research Institute, a RMB 4.5 billion R&D and manufacturing campus.[3](https://www.mindray.com/en/media-center/news/mindray-most-invested-rd-center-announced-construction)
| Fact | Detail |
|---|---|
| Incorporated | December 24, 2019, as 武汉迈瑞医疗技术研究院有限公司; renamed January 2024[1](https://www.tianyancha.com/company/3400983339) |
| Location | 828 Gaoxin Avenue, East Lake High-tech Development Zone, Wuhan[1](https://www.tianyancha.com/company/3400983339) |
| Ownership | 100% Mindray Medical[1](https://www.tianyancha.com/company/3400983339) |
| Sector | Medical diagnostic, monitoring, and treatment equipment manufacturing (C3581)[1](https://www.tianyancha.com/company/3400983339) |
| Registered capital | RMB 2 billion (paid-in RMB 500 million) after June 2025 increase[4](https://www.wuhan.gov.cn/sy/whyw/202508/t20250806_2629861.shtml) • [1](https://www.tianyancha.com/company/3400983339) |
| Legal representative | Han Le (韩乐)[1](https://www.tianyancha.com/company/3400983339) |
| Status | Deregistered December 3, 2025; merged into Wuhan Mindray Scientific Co., Ltd.[2](https://www.vcbeathealth.com/article/5290) |
## History and founding
Mindray incorporated the entity in Wuhan on December 24, 2019 under the name 武汉迈瑞医疗技术研究院有限公司, a name it kept until January 2024, when it was renamed 武汉迈瑞生物医疗科技有限公司.[1](https://www.tianyancha.com/company/3400983339) The incorporation followed Mindray's decision to build a second headquarters outside its Shenzhen base. Construction of the Mindray Wuhan Center, combining a research institute and a manufacturing center with a total investment of RMB 4.5 billion, officially launched on June 20, 2020 in the East Lake High-tech Development Zone, on a site of about 271 mu with roughly 620,000 square meters of planned construction area; Mindray described it as its future second-largest R&D center.[3](https://www.mindray.com/en/media-center/news/mindray-most-invested-rd-center-announced-construction)
## Products, technology and services
The Wuhan base, which opened in mid-2025, concentrates on three business lines: minimally invasive surgery, orthopedics, and cardiovascular products, spanning R&D, manufacturing, and customer training. According to Mindray's own announcement, the campus has about 530,000 square meters of built area.[5](https://www.mindray.com/cn/media-center/news/the-second-headquarters-of-mindray-group-wuhan-base-officially-opened) The Wuhan production base is one of Mindray's seven global supply-chain bases and produces orthopedic materials, minimally invasive surgical instruments, and biological raw materials.[5](https://www.mindray.com/cn/media-center/news/the-second-headquarters-of-mindray-group-wuhan-base-officially-opened)
The R&D side includes about 13,000 square meters of laboratory space with more than 90 laboratories and a global customer training center.[4](https://www.wuhan.gov.cn/sy/whyw/202508/t20250806_2629861.shtml) At the 2020 groundbreaking, Mindray said the research institute would cover biomaterial R&D, surgical equipment R&D, and "Big Health" technology, with 2,000 staff planned within five years, including 1,200 high-end R&D personnel; the manufacturing center was designed for an industrial output value of no less than RMB 3 billion at full operation.[3](https://www.mindray.com/en/media-center/news/mindray-most-invested-rd-center-announced-construction) The Wuhan city government reported a hiring plan of 2,000 employees within five years with 60% R&D talent, and quoted Mindray president Wu Hao describing Wuhan as a core part of the company's long-term strategy and its most important talent-supply base.[4](https://www.wuhan.gov.cn/sy/whyw/202508/t20250806_2629861.shtml)
## Capitalization (by the numbers)
The company's registered capital began at RMB 500 million. In June 2025 it was raised to RMB 2 billion, a 300% increase, while paid-in capital remained RMB 500 million; the increase was an internal infusion from the wholly owned parent, not external fundraising.[4](https://www.wuhan.gov.cn/sy/whyw/202508/t20250806_2629861.shtml) • [1](https://www.tianyancha.com/company/3400983339) Separately, Mindray announced on June 13, 2025 that IPO proceeds of RMB 5.93 billion gross (RMB 5.75 billion net) had been held in a special escrow account under this entity's name for the "Wuhan Research Institute project," which was by then complete, with surplus funds permanently converted to working capital.[6](https://iivd.net/article-41699-1.html) Mindray's 2024 annual report had stated the project, planned as the company's second-largest R&D center, would enter use in the first half of 2025 with phase-one construction complete and equipment installed.[6](https://iivd.net/article-41699-1.html) The 2024 annual report recorded 579 insured employees at the entity.[1](https://www.tianyancha.com/company/3400983339)
## Status and outcome: absorbed merger (December 2025)
In December 2025 Mindray consolidated its Wuhan entities. Wuhan Mairui Bio-Medical Technology filed for deregistration on December 3, 2025, with the reason recorded as "due to merger or division," and was absorbed by Wuhan Mindray Scientific Co., Ltd.[2](https://www.vcbeathealth.com/article/5290) On December 8, 2025, the surviving company's registered capital rose from RMB 300 million to RMB 2.3 billion, an increase of about 667%; Mindray Medical was added as shareholder, taking over from Mindray Technology Holdings as controlling shareholder, and the legal representative changed from Shi Peng to Han Le.[2](https://www.vcbeathealth.com/article/5290) • [7](https://www.innomd.org/article/a9c9ee1dbaf6ad8b60acc7806c8c3ac8.html) The merged entity's business scope covers R&D, production, and sales of Class I, II, and III medical devices.[2](https://www.vcbeathealth.com/article/5290) Mindray's 2025 annual report stated the deregistration had no material impact on overall operations or results.[8](https://www.iivd.net/article-45502-1.html)
## What the "RMB 2 billion" really measures
The RMB 2 billion figure that drew press attention is registered capital of a wholly owned subsidiary, not venture funding. Paid-in capital stayed at RMB 500 million, and the entity was merged away six months later, so the increase signals Mindray's commitment to its Wuhan campus rather than startup traction.[4](https://www.wuhan.gov.cn/sy/whyw/202508/t20250806_2629861.shtml) • [1](https://www.tianyancha.com/company/3400983339) Trade press also described the December 2025 restructuring of the successor entity as an "A-round financing," but the shareholder before and after was within the Mindray group, making it an internal reorganization rather than outside investment.[7](https://www.innomd.org/article/a9c9ee1dbaf6ad8b60acc7806c8c3ac8.html)
## Recent developments
- January 2024: renamed from 武汉迈瑞医疗技术研究院有限公司 to 武汉迈瑞生物医疗科技有限公司.[1](https://www.tianyancha.com/company/3400983339)
- June 13, 2025: Mindray closed out the IPO escrow account for the Wuhan Research Institute project and converted the surplus to working capital.[6](https://iivd.net/article-41699-1.html)
- June 2025: registered capital increased from RMB 500 million to RMB 2 billion.[4](https://www.wuhan.gov.cn/sy/whyw/202508/t20250806_2629861.shtml)
- July/August 2025: the Wuhan base officially opened (Mindray announced July 2025; the Wuhan government reported the opening in early August 2025).[5](https://www.mindray.com/cn/media-center/news/the-second-headquarters-of-mindray-group-wuhan-base-officially-opened) • [4](https://www.wuhan.gov.cn/sy/whyw/202508/t20250806_2629861.shtml)
- December 3–8, 2025: deregistration by merger; Wuhan Mindray Scientific became the sole operating Mindray entity in Wuhan, serving as the group's second growth center after Shenzhen.[2](https://www.vcbeathealth.com/article/5290) • [9](https://www.vcbeathealth.com/article/5344)
## References
1. [武汉迈瑞生物医疗科技有限公司 - 天眼查](https://www.tianyancha.com/company/3400983339)
2. [Mindray Completes Subsidiary Integration in Wuhan - VCBeat](https://www.vcbeathealth.com/article/5290)
3. [Mindray's most Invested R&D Center Announced Construction - Mindray](https://www.mindray.com/en/media-center/news/mindray-most-invested-rd-center-announced-construction)
4. [迈瑞医疗全球第二总部在汉开园 - 武汉市人民政府](https://www.wuhan.gov.cn/sy/whyw/202508/t20250806_2629861.shtml)
5. [迈瑞集团第二总部——武汉基地正式开园 - 迈瑞医疗](https://www.mindray.com/cn/media-center/news/the-second-headquarters-of-mindray-group-wuhan-base-officially-opened)
6. [增幅300%！迈瑞20亿大手笔 - 小桔灯网](https://iivd.net/article-41699-1.html)
7. [迈瑞旗下武汉子公司被吸收合并，获得A轮融资！ - 医谷](https://www.innomd.org/article/a9c9ee1dbaf6ad8b60acc7806c8c3ac8.html)
8. [迈瑞，注销两家子公司！ - 小桔灯网](https://www.iivd.net/article-45502-1.html)
9. [Mindray Completes Wuhan Business Integration - VCBeat](https://www.vcbeathealth.com/article/5344)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Medical device makers*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license